A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3892-3899

  Barger, Troy E ^a   Wrona, Deborah ^a   Goletz, Theresa J ^a   Mytych, Daniel T ^a  

^a Department of Clinical Immunology ^*  (United States)

Author keywords

ESA; PRCA; pre existing antibodies; SPRIA

Indexed keywords

ANTIANEMIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY MEDIATED PURE RED CELL APLASIA; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; NEPHROLOGY; ONCOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PURE RED CELL ANEMIA; SAMPLE; SURFACE PLASMON RESONANCE;

ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; AUTOANTIBODIES; ERYTHROPOIETIN; GLYCOSYLATION; HEMATINICS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; RED-CELL APLASIA, PURE; SELF TOLERANCE;

EID: 84868529788     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs392     Document Type: Article

References (41)

1. Kindt T, Goldsby R, Osborne B. Kuby Immunology, 6th edn. New York: W. H. Freeman and Company, 2007
2. Koren E, Zuckerman L, Mire-Sluis A. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3: 349-360
3. Stavnezer J. Molecular processes that regulate class switching. Curr Top Microbiol Immunol 2000; 245: 127-168
4. Wabl M, Steinberg C. Affinity maturation and class switching. Curr Opin Immunol 1996; 8: 89-92
5. Pollock C, Johnson D, Hörl Wet al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199
6. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotech 2006; 24: 613-614
7. Cui Z, Zhao M-h, Segelmark M et al. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010; 78: 590-597
8. Bendtzen K, Hansen MB, Ross C et al. High-avidity autoantibodies to cytokines. Immunol Today 1998; 19: 209-211
9. Avrameas S, Ternynck T, Tsonis IA et al. Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun 2007; 29: 213-218
10. Swanson SJ. Detection of baseline anti-erythropoietin antibodies in patients with chronic kidney disease, using the BIAcore immunoassay. In: Paper Presented at the European Renal Association-European Dialysis Transplant Association, Lisbon, Portugal, 2004
11. Wu G, Wadgymar A, Wong G et al. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving Epoetin alfa in 5 Ontario renal centers. Am J Kidney Dis 2004; 44: 264-269
12. Swanson SJ, Ferbas J, Mayeux P et al. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004; 96: c88-c95
13. Swanson SJ, Mytych D. The use of surface plasmon resonance for the detection and characterization of antibodies. In: Michael G Tovey (ed). Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Hoboken, NJ: John Wiley & Sons, Inc, 2011, pp. 193-210
14. Barger TE, Kuck AJ, Chirmule N et al. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol Dial Transplant 2012; 27: 688-693
15. Schett G, Firbas U, Füreder Wet al. Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology 2001; 40: 424-431
16. Sipsas NV, Kokori SI, Ioannidis JPA et al. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus Type 1-related anemia. J Infect Dis 1999; 180: 2044-2047
17. Committee for Medicinal Products (CHMP) For Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006, 2007 http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003946.pdf
18. Henck JW, Hilbish KG, Serabian MA et al. Reproductive toxicity testing of therapeutic biotechnology agents. Teratology 1996; 53: 185-195
19. Krigel RL, Padavic-Shaller KA, Rudolph AR et al. A Phase I Study of recombinant interleukin 2 plus recombinant β-interferon. Cancer Res 1988; 48: 3875-3881
20. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000; 48: 706-712
21. Mytych D, La S, Barger T et al. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and Epoetin alfa in human serum. J Pharm Biomed Anal 2009; 49: 415-426
22. Narhi LO, Arakawa T, Aoki KH et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 1991; 266: 23022-6
23. Wei X, Swanson S, Gupta S. Development and validation of a cellbased bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J Immunol Methods 2004; 293: 115-126
24. Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347
25. Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353
26. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005; 18: 381-387
27. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48: 1754-1762
28. Pang J, Blanc T, Brown J et al. Recognition and Identification of UV-absorbing Leachables in EPREX® pre-filled syringes: an unexpected occurrence at a formulation-component interface. PDA J Pharm Sci Technol 2007; 61: 423-432
29. Rossert J, Casadevall N, Eckardt K-U. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406
30. Vroom A, Vulto A. Safety study for subcutaneous Epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended posted 07/10/2009. Generics and Biosimilars Initiative, 2009. http://www. gabionline.net/Biosimilars/News/ Safety-study-for-subcutaneousepoetin-alfa-biosimilar-Binocrit-Epoetin-alfa- Hexal-Abseamedsuspended
31. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008; 74: 1617-1622
32. Brändlein S, Pohle T, Ruoff N et al. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003; 63: 7995-8005
33. Vollmers HP, Brändlein S. Natural IgM antibodies: the orphaned molecules in immune surveillance. Adv Drug Deliv Rev 2006; 58: 755-765
34. Diaw L, Magnac C, Pritsch O et al. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol 1997; 158: 968-976
35. Ghaderi D, Taylor RE, Padler-Karavani V et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotech 2010; 28: 863-867
36. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626-3634
37. Tatarewicz S, Wei X, Gupta S et al. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007; 27: 620-627
38. Tzioufas AG, Kokori SIG, Petrovas CI et al. Autoantibodies to human recombinant eythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum 1997; 40: 2212-2216
39. Gross J, Moller R, Bischoff S et al. Detection and characterization of antibodies against recombinant erythropoietin human erythropoietin by RIPA, ELISA and neutralization assay in patients with renal anemia. J Immunol Methods 2008; 336: 152-158
40. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 7: 469
41. Thorpe R, Swanson S. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005; 20(Suppl 4): iv16-iv22